ONC Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.24%

Insider Buying (Last 12 Months): C$0.00

Insider Selling (Last 12 Months): C$0.00

Oncolytics Biotech Insider Trading History Chart

Oncolytics Biotech Share Price & Price History

C^$1.43

▼ -0.03 (-2.05%)

As of 04/23/2024 01:00 AM ET

Days: 30 | 90 | 365

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

Oncolytics Biotech Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/16/2022	Allison Hagerman	Senior Officer	Buy	4,200	C$1.16	C$4,851.00	4,200
6/14/2022	Kirk Look	Senior Officer	Buy	6,000	C$1.11	C$6,656.40	39,028
6/14/2022	Matthew Coffey	Director	Buy	5,774	C$1.08	C$6,219.46	88,433
6/7/2021	Angela Frances Holtham	Director	Buy	7,000	C$3.59	C$25,123.70	108,336

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad

Claim your free seat by clicking here now.

SEC Filings (Institutional Ownership Changes) for Oncolytics Biotech (TSE:ONC)

6.98% of Oncolytics Biotech stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Today's Range

Now: C$1.43

C$1.43

C$1.46

50 Day Range

MA: C$1.44

C$1.24

C$1.59

52 Week Range

Now: C$1.43

C$1.20

C$4.49

Volume

22,910 shs

Average Volume

78,062 shs

Market Capitalization

C$107.85 million

P/E Ratio

N/A

Dividend Yield

0.31%

Beta

1.49

Who are the company insiders with the largest holdings of Oncolytics Biotech?: Oncolytics Biotech's top insider shareholders include:
Matthew Coffey (Director)
Kirk Look (Senior Officer)
Allison Hagerman (Senior Officer)
Learn More about top insider investors at Oncolytics Biotech.